Back to results
US 2026/0097074 A1Published application
Erythroid lineages derived from pluripotent cells
AssigneeStratus Therapeutics, Inc.
InventorDhvanit Shah
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeStratus Therapeutics, Inc.
InventorDhvanit Shah
Estimating the term…
The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.
A method for preparing a cell population of an erythroid lineage, the method comprising:
(canceled)
(canceled)
9-10. (canceled)
15-20. (canceled)
The method of claim 120, wherein the induction of endothelial-to-hematopoietic transition comprises Piezol activation:
22-27. (canceled)
29-38. (canceled)
A hematopoietic stem cell (HSC) or erythroid progenitor composition, wherein the HSCs or erythroid progenitors express an erythropoietin receptor (EPOR) that is hyperresponsive to EPO.
41-46. (canceled)
48-56. (canceled)
The composition of claim 48, wherein HSCs are prepared from iPSCs in a process that comprises Piezol activation;
58-59. (canceled)
A method for making an HSC population, comprising:
61-74. (canceled)
78-84. (canceled)
Dependencies are inferred from the claim text.